ATE394419T1 - Peptidantagonisten von dp transkriptionsfaktoren - Google Patents

Peptidantagonisten von dp transkriptionsfaktoren

Info

Publication number
ATE394419T1
ATE394419T1 AT97950295T AT97950295T ATE394419T1 AT E394419 T1 ATE394419 T1 AT E394419T1 AT 97950295 T AT97950295 T AT 97950295T AT 97950295 T AT97950295 T AT 97950295T AT E394419 T1 ATE394419 T1 AT E394419T1
Authority
AT
Austria
Prior art keywords
transcription factors
peptide
peptide antagonists
protein
cell
Prior art date
Application number
AT97950295T
Other languages
English (en)
Inventor
Thangue Nicholas Barrie La
Lasantha Bandara
Original Assignee
Topotarget Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topotarget Uk Ltd filed Critical Topotarget Uk Ltd
Application granted granted Critical
Publication of ATE394419T1 publication Critical patent/ATE394419T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Prostheses (AREA)
AT97950295T 1996-12-20 1997-12-22 Peptidantagonisten von dp transkriptionsfaktoren ATE394419T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9626589.7A GB9626589D0 (en) 1996-12-20 1996-12-20 Peptides

Publications (1)

Publication Number Publication Date
ATE394419T1 true ATE394419T1 (de) 2008-05-15

Family

ID=10804818

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97950295T ATE394419T1 (de) 1996-12-20 1997-12-22 Peptidantagonisten von dp transkriptionsfaktoren

Country Status (11)

Country Link
US (2) US6268334B1 (de)
EP (1) EP0956299B1 (de)
JP (1) JP2001506863A (de)
AT (1) ATE394419T1 (de)
AU (1) AU735032B2 (de)
CA (1) CA2271715A1 (de)
DE (1) DE69738671D1 (de)
GB (1) GB9626589D0 (de)
IL (1) IL130557A0 (de)
NZ (1) NZ336530A (de)
WO (1) WO1998028334A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
GB9901710D0 (en) 1999-01-26 1999-03-17 Prolifix Ltd Peptide inhibitors
AU3230200A (en) * 1999-02-12 2000-08-29 Pioneer Hi-Bred International, Inc. Transgenic plants with modified expression of the dp protein
FR2796952B1 (fr) * 1999-07-30 2003-08-15 Centre Nat Rech Scient Nouvelles applications de peptides issus du domaine cytoplasmique du precurseur de la proteine amyloide
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
ES2279441T3 (es) * 2003-09-19 2007-08-16 Astrazeneca Ab Derivados de quinazolina.
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
US9550981B2 (en) 2014-01-22 2017-01-24 University Of Washington Modified tafazzin proteins and methods of making and using the same
WO2016094791A1 (en) * 2014-12-12 2016-06-16 University Of Washington Methods for treating and preventing cardiomyopathy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ257181A (en) * 1992-10-29 1997-07-27 Medical Res Council Transcription factor dp-1, dna, vectors and host cells therefor
GB9610195D0 (en) * 1996-05-15 1996-07-24 Medical Res Council Assay

Also Published As

Publication number Publication date
US6268334B1 (en) 2001-07-31
US7160981B2 (en) 2007-01-09
DE69738671D1 (de) 2008-06-19
CA2271715A1 (en) 1998-07-02
NZ336530A (en) 2000-11-24
AU735032B2 (en) 2001-06-28
US20020103121A1 (en) 2002-08-01
IL130557A0 (en) 2000-06-01
EP0956299B1 (de) 2008-05-07
WO1998028334A1 (en) 1998-07-02
AU5330498A (en) 1998-07-17
GB9626589D0 (en) 1997-02-05
EP0956299A1 (de) 1999-11-17
JP2001506863A (ja) 2001-05-29

Similar Documents

Publication Publication Date Title
NZ501767A (en) Cyclic integrin binding peptide with the amino acid sequence RKK
DE69826661D1 (de) Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung
WO1998020133A3 (en) Proteins with enhanced levels of essential amino acids
WO1996017924A3 (en) Novel hedgehog-derived polypeptides
GB9712512D0 (en) A method for in vitro molecular evolution of protein function
WO1995030750A3 (fr) Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
DE69535948D1 (de) Von wd-40 abstammende peptide und ihre verwendung
WO1998022574A3 (de) Rekombinante collagenase typ i aus clostridium histolyticum und ihre verwendung zur isolierung von zellen und zellverbänden
RU94036776A (ru) Домен ингибитора протеазы, днк, вектор, клетка, способ получения ингибитора протеазы, фармацевтическая композиция, применение домена ингибитора протеазы
ATE394419T1 (de) Peptidantagonisten von dp transkriptionsfaktoren
WO1996017935A3 (en) Rantes peptide and fragments and compositions comprising it for treatment of inflammation
DE69735502D1 (de) Mutanten des lag-3 proteins, ihre expression und verwendung
DK0479912T3 (da) Fremgangsmåde til hæmning af N-endereglens forløb i levende celler
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
IL125771A0 (en) Recombinant ribonuclease proteins
DE69631972D1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
EP0082568A3 (en) Retro-inverso analogues of c-terminal penta and hexapeptides of substance p.
NZ230654A (en) Anti-cell proliferative penta and hexa peptides
WO2000001802A3 (en) Peptide antagonists of the human urokinase receptor and method for selecting them
ATE291088T1 (de) Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe
RU97112745A (ru) Варианты апротинина с улучшенными свойствами
WO1998017626A3 (en) Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
DK0946591T3 (da) Klonede glucagon-lignende peptid-2 receptorer
DK107389A (da) Modificerede proteiner

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties